News
Public · Published
SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval Forecast
BlackRock disclosed owning 15.87 million shares of Sellas Life Sciences, a 7.9% stake, up about 31% from its March-end holding. SLS closed Tuesday up 7% at $12.17. Traders circulated European forecasts pointing to possible 2027 approval of its leukemia immunotherapy GPS ahead of Phase 3 results.
Published:
Updated:
What happened
BlackRock disclosed owning 15.87 million shares of Sellas Life Sciences, a 7.9% stake, up about 31% from its March-end holding. SLS closed Tuesday up 7% at $12.17. Traders circulated European forecasts pointing to possible 2027 approval of its leukemia immunotherapy GPS ahead of Phase 3 results.
Confirmed
Global impact / market context
A large investor like BlackRock holding more shares can signal confidence and may draw attention from other buyers, which can support the stock price. The 2027 European approval forecasts give investors a potential future milestone, but they remain estimates and could shift.
Analyst inference
The stock moved higher as attention focused on the BlackRock stake and the upcoming Phase 3 Regal trial data. The trial compares GPS with best available therapy in acute myeloid leukemia, and overall survival is the key measure watched for results.
Analyst inference
What to watch
- Final analysis of the Phase 3 Regal trial is triggered by the 80th death across treatment groups, so investors will watch for that event and the resulting overall survival data. Confirmed
- European forecasts list possible GPS approval in 2027, with one report citing November 1, 2027 and another citing April 2027, which investors may track as potential timeline signals. Proposed
- If Regal data show better overall survival, that could raise expectations for approval and revenue, while weak data could lower them and affect how investors value the company. Analyst inference